KRAS and acute myeloid leukemia: What’s more, an adverse prognostic impact of KRAS mutations was confirmed in adult MLL-r AML; KRAS mutations were associated with adverse prognoses in pediatric patients with both high-risk (MLLT10+MLLT4+MLLT1; n = 60) and intermediate-to-low-risk (MLLT3+ELL+others; n = 100) MLL fusions (70).